BCDA just entered a long with members. $1.24 Stage 3 clinical trials will be approaching soon and we could see this name get a 100-1000% gain on any positive news.
Multiple insiders have accumulated this month and we seem to be forming a high volume bottom.
Stock price briefly dipped below the warrant price of a $1.25 offered to investors...signalling an undervalued trade.
Biotech has seen some strong buying across the XBI etf.
